U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2
Molecular Weight 162.2316
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOTINE

SMILES

CN1CCC[C@H]1C2=CN=CC=C2

InChI

InChIKey=SNICXCGAKADSCV-JTQLQIEISA-N
InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H14N2
Molecular Weight 162.2316
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment: description was created based on several sources, including https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/

Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NICORETTE

Approved Use

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 ng/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6 ng × h/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 min
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Bradycardia...
AEs leading to
discontinuation/dose reduction:
Bradycardia (1 patient)
Sources:
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Allergic dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic dermatitis (1 patient)
Sources:
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Hypersensitivity, Nausea...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (1 patient)
Nausea (1 patient)
Sources:
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Depression, Nausea...
AEs leading to
discontinuation/dose reduction:
Depression (1 patient)
Nausea (grade 2-3, 2 patients)
Sources:
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Other AEs: Nausea...
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
Disc. AE
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Allergic dermatitis 1 patient
Disc. AE
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Hypersensitivity 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Depression 1 patient
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea grade 2-3, 2 patients
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Death grade 5, 1 patient
Disc. AE
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Nausea
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Chronic nicotine pretreatment protects the blood-brain barrier against nicotine-induced seizures in the rat.
1999 Sep
Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
2000 Jan
CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
2000 Jan
Dermal exposure to pesticides modifies antioxidant enzymes in tissues of rats.
2000 Jul
Antioxidant effect of onion oil (Allium cepa. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol.
2000 Jul 27
Nicotine switches the form of H(2)O(2)-induced cell death from apoptosis to necrosis in U937 cells.
2000 Jun 1
An animal model of adolescent nicotine exposure: effects on gene expression and macromolecular constituents in rat brain regions.
2000 Jun 9
Prenatal nicotine exposure is associated with an increase in [125I]epibatidine binding in discrete cortical regions in rats.
2000 Oct
Effects of nicotine on the intervertebral disc: an experimental study in rabbits.
2001
Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: evidence of calbindin-D28K overexpression.
2001
Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal.
2001 Feb
Cardiovascular effects of transdermal nicotine in mildly hypertensive smokers.
2001 Jul
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
2001 Jun
Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism.
2001 Jun
A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
2001 Mar 2
Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.
2001 Sep
Efficient enantiomeric synthesis of pyrrolidine and piperidine alkaloids from tobacco.
2001 Sep 21
Fetal and adolescent nicotine administration: effects on CNS serotonergic systems.
2001 Sep 28
[Acute confusional syndrome due to acute nicotine withdrawal].
2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
2002 Feb
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
2002 Jan 11
Involvement of human heat shock protein 90 alpha in nicotine-induced apoptosis.
2002 Jul 1
beta 2 nicotinic acetylcholine receptor subunit modulates protective responses to stress: A receptor basis for sleep-disordered breathing after nicotine exposure.
2002 Oct 1
Lasting effects of adolescent nicotine exposure on the electroencephalogram, event related potentials, and locomotor activity in the rat.
2002 Sep 20
How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.
2014 Jan
Patents

Sample Use Guides

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.
Route of Administration: Other
Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:07:38 GMT 2023
Edited
by admin
on Fri Dec 15 15:07:38 GMT 2023
Record UNII
6M3C89ZY6R
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
NICOTINE
EP   HSDB   ISO   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Systematic Name English
NICOTINE [HSDB]
Common Name English
NSC-5065
Code English
Nicotine [WHO-DD]
Common Name English
NICODERM CQ
Brand Name English
NICOTINE [ISO]
Common Name English
NICOTINE [MI]
Common Name English
PYRIDINE, 3-((2S)-1-METHYL-2-PYRROLIDINYL)-
Systematic Name English
NICOTINE [VANDF]
Common Name English
PROSTEP
Brand Name English
3-((2S)-1-METHYLPYRROLIDIN-2-YL)PYRIDINE
Systematic Name English
3-((2S)-1-METHYL-2-PYRROLIDINYL)PYRIDINE
Systematic Name English
HABITROL
Brand Name English
NICOTINUM
HPUS  
Common Name English
NICOTINE COMPONENT OF COMMIT
Brand Name English
NICOTINE (TPD)
Common Name English
NICOTINE [EP MONOGRAPH]
Common Name English
NICOTINE [USP MONOGRAPH]
Common Name English
NICOTINUM [HPUS]
Common Name English
NICOTINE [ORANGE BOOK]
Common Name English
NICOTINE COMPONENT OF NICORETTE
Brand Name English
β-Pyridyl-α-N-methyl pyrrolidine
Common Name English
NICOTINE S(-)
Common Name English
NICOTROL
Brand Name English
NICOTINE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C221
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
LIVERTOX NBK548698
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
WHO-ATC N07BA01
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
NDF-RT N0000175706
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
WHO-VATC QP53AX13
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
WHO-VATC QN07BA01
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
EPA PESTICIDE CODE 56702
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
NDF-RT N0000006496
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
NCI_THESAURUS C73579
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
NDF-RT N0000006496
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
Code System Code Type Description
MESH
D009538
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
RXCUI
7407
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
SMS_ID
100000079991
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
IUPHAR
2585
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
NCI_THESAURUS
C691
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
WIKIPEDIA
Nicotine replacement therapy
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
CHEBI
17688
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
PUBCHEM
89594
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
HSDB
1107
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
WIKIPEDIA
NICOTINE
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL3
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
DRUG BANK
DB00184
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID1020930
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
EVMPD
SUB14645MIG
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
LACTMED
Nicotine
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
CAS
54-11-5
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
ALANWOOD
nicotine
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
EVMPD
SUB30160
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
DRUG CENTRAL
1920
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
MERCK INDEX
m7879
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY Merck Index
NSC
5065
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
FDA UNII
6M3C89ZY6R
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-193-3
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
DAILYMED
6M3C89ZY6R
Created by admin on Fri Dec 15 15:07:38 GMT 2023 , Edited by admin on Fri Dec 15 15:07:38 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> AGONIST
NICOTINE IS AN ANTIHERBIVORY ALKALOID AND POTENT PARASYMPATHOMIMETIC STIMULANT AND FOUND IN PLANTS, MOSTLY THOSE IN THE NIGHTSHADE FAMILY. NICOTINE ACTS AS A RECEPTOR AGONIST AT MOST NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS), EXCEPT AT TWO NICOTINIC RECEPTOR SUBUNITS (NACHR.ALPHA.9 AND NACHR.ALPHA.10) WHERE IT ACTS AS A RECEPTOR ANTAGONIST.
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
SALT/SOLVATE -> PARENT
DERIVATIVE -> PARENT
Carcinogenic substance present in cigarette smoke
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INHIBITOR
TARGET -> INHIBITOR
BINDING
IC50
METABOLIC ENZYME -> SUBSTRATE
SUB_CONCEPT->SUBSTANCE
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Nicotine (mg/cigarette) Domestic = 12.6 SD(1.6) Imported = 11.1 SD(2.2)
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
INHIBITOR -> TARGET
BINDS TO NICOTINE PREVENTS ACTION
SUB_CONCEPT->SUBSTANCE
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
75% is converted into cotintine which is further metabolized.
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
circulating nicotine is metabolized to cotinine by cytochrome P450 and aldehyde oxidase
MAJOR
METABOLITE -> PARENT
in animals both N-oxide isomers form, in humans only the transisomers form.
MAJOR
URINE
METABOLITE -> PARENT
The extent of nicotine N-glucuronidation by African Americans is significantly lower than by Whites.
METABOLITE -> PARENT
PLASMA; URINE
METABOLITE -> PARENT
The extent of Cotinine N-glucuronidation by African Americans is significantly lower than by Whites.
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC